Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Does nonmetastatic castration-resistant prostate cancer still exist?

Nature Reviews Clinical Oncology volume 15, pages 350–351 (2018)Cite this article

Subjects

After almost 20 years of negative trials of novel therapies for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), two androgen receptor antagonists have shown favourable outcomes in phase III trials involving patients with high-risk nmCRPC. Herein, the history of nmCRPC and clinical trials in this disease setting are discussed and a perspective on molecular imaging and clinical management of nmCRPC is offered.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Scher, H. I. & Heller, G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55, 323–327 (2000).

    Article  PubMed  CAS  Google Scholar 

  2. Smith, M. R. et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J. Clin. Oncol. 23, 2918–2925 (2005).

    Article  PubMed  Google Scholar 

  3. Smith, M. R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial. Lancet 379, 39–46 (2012).

    Article  PubMed  CAS  Google Scholar 

  4. Smith, M. R. et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J. Clin. Oncol. 31, 3800–3806 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Nelson, J. B. et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113, 2478–2487 (2008).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Nelson, J. B. et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118, 5709–5718 (2012).

    Article  PubMed  CAS  Google Scholar 

  7. Small, E. J. et al. SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) [abstract]. J. Clin. Oncol. 36 (Suppl. 6), 161 (2018).

    Article  Google Scholar 

  8. Hussain, M. et al. PROSPER: a phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) [abstract]. J. Clin. Oncol. 36 (Suppl. 6), 3 (2018).

    Article  Google Scholar 

  9. Smith, M. R. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 378, 1408–1418 (2018).

    Article  PubMed  CAS  Google Scholar 

  10. Xie, W. et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J. Clin. Oncol. 35, 3097–3104 (2017).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Yu, E. Y. et al. Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. J. Urol. 188, 103–109 (2012).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Terada, N. et al. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy naïve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. Int. J. Urol. 24, 441–448 (2017).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA

    Celestia S. Higano

Authors
  1. Celestia S. Higano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Celestia S. Higano.

Ethics declarations

Competing interests

C.S.H. has served on advisory boards and/or steering committees for Astellas, Bayer, Blue Earth Diagnostics, Clovis Oncology, Ferring, Janssen, Myriad, and Tolmar, has received Institutional research funding from Aptevo, Aragon, Astellas, AstraZeneca, Bayer, Hoffman LaRoche, Janssen, Medivation, and Pfizer, and declares that her spouse is a co-founder of, and has a leadership role at, CTI Biopharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Higano, C.S. Does nonmetastatic castration-resistant prostate cancer still exist?. Nat Rev Clin Oncol 15, 350–351 (2018). https://doi.org/10.1038/s41571-018-0025-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-018-0025-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing